Trial Profile
Phase II Study of Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2019
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 08 Jul 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 09 Jul 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 09 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.